Supplementary Material 1: Diagnosis categorization code

Diagnosis categorization
Sepsis [DA40-DA42]
Other Infections (not pneumonia or sepsis) [DA42-DC)
Cancer [DC00-DD48)
Anemia (DD62-DD65)
Other Endocrine, nutritional and metabolic diseases [DE-DF)
Diabetes [including hypoglycemia and ketoacidosis) [DE11-DE17)
Electrolytes and volume disorders [DE70-DE89)
Mental and behavioral disorders [DF00-DG)
Diseases of the nervous system [DG-DH)
Other cardiac diseases [DI-DJ)
Hypertensive disease [DI10-DI16)
Acute coronary syndrome [DI20-DI23)
Pulmonary embolism [DI26-DI27)
Atrial fibrillation [DI48-DI49)
Heart failure [DI50-DI51)
Heart disease unspecified [DI519-DI52)
Other pulmonary disorders [DJ-DK)
Pneumonia [including influenza and other viral) [DJ09-DJ189, DJ20-DJ21, DJ22-DJ23)
Chronic obstructive pulmonary disease [DJ41-DJ45)
Asthma [DJ45-DJ47)
Interstitial lung disease (including sarcoidosis of lung) [DJ60-DJ70, DJ84-DJ85, DD86-DD87)
Pulmonary edema [DJ81-DJ82)
Pyothorax [DJ86-DJ87)
Pleural effusion [DJ90-DJ91, DJ948-DJ949)
Pneumothorax (including traumatic) [DJ93-DJ94, DS270-DS270)
Respiratory failure [DJ96)
Diseases of the digestive system [DK-DL)

 Diseases of the musculoskeletal system and connective tissue [DM-DN)

 Other diseases of the genitourinary system [DN-DO)

 Cystitis or Urinary tract infection unspecified [DN30-DN31, DN390-DN391)

 Pregnancy, childbirth, and the puerperium [DO-DP)

 Symptoms, signs, and abnormal clinical and laboratory findings, not elsewhere classified [DR-DS)

 Dyspnea (R06.0) [DR060-DR061)

 Injury, poisoning and certain other consequences of external causes [DS-DU)

 Observation (Z03) [DZ03-DZ04)

 Other factors influencing health status and contact with health services (other Z-diagnoses) (DZ)

All intervals are half-open intervals where the right endpoint is excluded in the set.

Supplementary Material 2: RECORD checklist

The RECORD statement – checklist of items, extended from the STROBE statement, that should be reported in observational studies using routinely collected health data.

	ltem No.	STROBE items	Location in manuscript where items are reported	RECORD items	Location in manuscript where items are reported
Title and abstract	t				
	1	(a) Indicate the study's design with a commonly used term in the title or the abstract (b) Provide in the abstract an informative and balanced summary of what was done and what was found		RECORD 1.1: The type of data used should be specified in the title or abstract. When possible, the name of the databases used should be included. RECORD 1.2: If applicable, the geographic region and timeframe within which the study took place should be reported in the title or abstract. RECORD 1.3: If linkage between databases was conducted for the study, this should be clearly stated in the title or abstract.	1
Introduction					•
Background rationale	2	Explain the scientific background and rationale for			3

		the investigation being reported		
Objectives	3	State specific objectives, including any prespecified hypotheses		3
Methods				
Study Design	4	Present key elements of study design early in the paper		4
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection		4
Participants	6	(a) Cohort study - Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> - Give the eligibility criteria, and the sources and methods of case	RECORD 6.1: The methods of study population selection (such as codes or algorithms used to identify subjects) should be listed in detail. If this is not possible, an explanation should be provided.	4
		ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> - Give the eligibility criteria, and the sources and methods of selection of participants	RECORD 6.2: Any validation studies of the codes or algorithms used to select the population should be referenced. If validation was conducted for this study and not published elsewhere, detailed methods and results should be provided.	
		(b) Cohort study - For matched studies, give matching criteria and number of exposed and unexposed	RECORD 6.3: If the study involved linkage of databases, consider use of a flow diagram or other graphical display to demonstrate the data linkage process, including the number	

Variables	7	Case-control study - For matched studies, give matching criteria and the number of controls per caseClearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic	of individuals with linked data at each stage. RECORD 7.1: A complete list of codes and algorithms used to classify exposures, outcomes, confounders, and effect modifiers should be	5
		criteria, if applicable.	provided. If these cannot be reported, an explanation should be provided.	
Data sources/ measurement	8	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group		6
Bias	9	Describe any efforts to address potential sources of bias		
Study size	10	Explain how the study size was arrived at		
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen, and why		5
Statistical methods	12	 (a) Describe all statistical methods, including those used to control for confounding (b) Describe any methods used to examine subgroups and interactions (c) Explain how missing data were addressed 		6

		 (d) Cohort study - If applicable, explain how loss to follow-up was addressed Case-control study - If applicable, explain how matching of cases and controls was addressed Cross-sectional study - If applicable, describe analytical methods taking account of sampling strategy (e) Describe any sensitivity analyses 		
Data access and cleaning methods			RECORD 12.1: Authors should describe the extent to which the investigators had access to the database population used to create the study population. RECORD 12.2: Authors should provide information on the data cleaning methods used in the study.	6
Linkage			RECORD 12.3: State whether the study included person-level, institutional-level, or other data linkage across two or more databases. The methods of linkage and methods of linkage quality evaluation should be provided.	6
Results		· · · · · · · · · · · · · · · · · · ·	· · · · · ·	
Participants	13	(a) Report the numbers of individuals at each stage of the study (<i>e.g.</i> , numbers potentially eligible, examined for eligibility,	RECORD 13.1: Describe in detail the selection of the persons included in the study (<i>i.e.</i> , study population selection) including filtering based on	7

		 confirmed eligible, included in the study, completing follow- up, and analysed) (b) Give reasons for non- participation at each stage. (c) Consider use of a flow diagram 	data quality, data availability and linkage. The selection of included persons can be described in the text and/or by means of the study flow diagram.	
Descriptive data	14	 (a) Give characteristics of study participants (<i>e.g.</i>, demographic, clinical, social) and information on exposures and potential confounders (b) Indicate the number of participants with missing data for each variable of interest (c) <i>Cohort study</i> - summarise follow-up time (<i>e.g.</i>, average and total amount) 		7
Outcome data	15	Cohort study - Report numbers of outcome events or summary measures over time Case-control study - Report numbers in each exposure category, or summary measures of exposure Cross-sectional study - Report numbers of outcome events or summary measures		7-8
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder- adjusted estimates and their precision (e.g., 95% confidence interval). Make clear which		7-8

		confounders were adjusted for and why they were included (b) Report category boundaries when continuous variables were categorized (c) If relevant, consider translating estimates of relative risk into absolute risk for a		
Other analyses	17	meaningful time period Report other analyses done— e.g., analyses of subgroups and interactions, and sensitivity analyses		
Discussion				
Key results	18	Summarise key results with reference to study objectives		8
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	RECORD 19.1: Discuss the implications of using data that were not created or collected to answer the specific research question(s). Include discussion of misclassification bias, unmeasured confounding, missing data, and changing eligibility over time, as they pertain to the study being reported.	10
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence		11

Generalisability	21	Discuss the generalisability (external validity) of the study results		8-9
Other Informatio	n			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based		
Accessibility of protocol, raw data, and programming code			RECORD 22.1: Authors should provide information on how to access any supplemental information such as the study protocol, raw data, or programming code.	

*Reference: Benchimol EI, Smeeth L, Guttmann A, Harron K, Moher D, Petersen I, Sørensen HT, von Elm E, Langan SM, the RECORD Working Committee. The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) Statement. *PLoS Medicine* 2015; in press.

*Checklist is protected under Creative Commons Attribution (<u>CC BY</u>) license.